Posts Tagged ‘announcement’
Firebrick Consultant to drive Pharmacy Distribution in Singapore
Firebrick Pharma (ASX:FRE) is pleased to announce that it has executed a consulting agreement (Agreement) with Keith Shortall, a former senior executive of Johnson & Johnson Consumer Health Asia-Pacific (J&J Consumer Health APAC). The primary goal of the Agreement is to establish pharmacy distribution for Nasodine in Singapore. Secondary objectives include evaluating potential distribution to…
Nasodine European Marketing Application filed and passed validation
Firebrick Pharma (ASX:FRE) is pleased to announce that it has filed a Marketing Authorisation Application (“MAA”) in Europe for the approval of Nasodine® Nasal Spray as a nasal antiseptic. The MAA has successfully passed validation and has now entered the evaluation phase. The application was filed via a decentralised procedure, where one EU member state,…
Firebrick Launches Nasodine in Singapore via Nasodine-sg.com
Firebrick Pharma Limited (ASX:FRE) is proud to announce that its product, Nasodine® Nasal Spray, is now available for sale in Singapore. Customers will be able to order the product through Firebrick’s new website dedicated to support Singapore sales: www.nasodine-sg.com In Singapore, Nasodine is classified as a topical antiseptic and does not require approval or licensing…
Nasodine Phase 2 COVID-19 Trial Results Published
The Company is now advanced in our plans to introduce Nasodine in at least one international market.
Firebrick Phase 3 Trial fully recruited with 500 subjects
Firebrick Pharma is pleased to announce that its Phase 3 trial of Nasodine® Nasal Spray in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled. “Subject to availability of the complete efficacy data and timely completion of the statistical analysis, we expect to report headline results of the trial by…
Nasodine COVID-19 Trial Achieves Primary Endpoint
Highlights Firebrick Pharma Limited is pleased to announce that its Phase 2 trial of Nasodine® Nasal Spray in COVID-19 achieved its primary endpoint. The primary endpoint was the reduction in viral load of SARS-CoV-2 over 4 days, based on culturable virus from throat and nasal swabs. Nasodine treatment resulted in 100% reduction by day 4,…
Investor Update on Key Projects
We are pleased to provide the following update on the Company’s key projects, which will be provided verbally by the Executive Chairman at a General Meeting of Shareholders, today. Phase 3 clinical trial of Nasodine® Nasal Spray (Nasodine): This trial started in 2022 and is a pivotal trial of Nasodine as a treatment for the…
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
Firebrick Pharma is pleased to provide an update on the progress of the confirmatory Phase 3 clinical trial of Nasodine® Nasal Spray as a treatment for the common cold. The study, which commenced in 2022, aims to recruit 196 subjects with early-stage colds who are confirmed by PCR to have a viral infection (other than…
Nasodine Patent Allowed in Canada
Highlights Firebrick Pharma Limited (ASX:FRE) is pleased to announce that its core patent covering Nasodine® Nasal Spray as a treatment and preventative for the common cold has now been allowed in Canada. Once this proceeds to grant, it will bring the number of countries where this patent has been granted to 28, now covering North…
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
Firebrick Pharma is pleased to announce that its Phase 2 COVID-19 trial of Nasodine® Nasal Spray has closed for recruitment.